{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:21:44Z","timestamp":1795022504894,"version":"4.10.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:p>\n                    Metformin, as a drug for treating type 2 diabetes, has been found to have a positive impact on mental health. This study will assess the potential causal relationship between metformin exposure and the risk of bipolar disorder (BD). We used publicly available genome-wide association studies statistical data to conduct 2-sample bidirectional Mendelian randomization (MR) analysis to determine the causal relationship between genetic susceptibility to metformin and BD risk. Genome-wide significant single nucleotide polymorphisms, that are associated with metformin use were selected as the instrumental variables. To determine the causal relationship between metformin exposure and BD, MR analysis was conducted, employing methods such as instrumental variable weighting. We applied complementary methods, including weighted median, weighted mode, simple mode, MR-Egger regression, and MR-pleiotropy residual sum and outlier to detect and correct for the effect of horizontal pleiotropy. Cochran\n                    <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                    statistics were used to assess instrument heterogeneity. The leave-one-out method was conducted for sensitivity analysis. The instrumental variable weighting analysis demonstrated that there was a significant causal relationship between the metformin exposure and BD risk [odds ratio [OR] (95% confidence interval [CI])\u2005=\u20050.032 (0.002\u20130.593),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.021] (ebi-a-GCST003724), [OR (95% CI)\u2005=\u20051.452E\u201004 (1.442E\u201007 to 1.463E\u201001),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.012] (ieu-a-800), [OR (95% CI)\u2005=\u20050.33 (0.27\u20130.404),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.000] (ieu-a-808). The sensitivity analysis revealed no heterogeneity in the individual results (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), and no significant publication bias. This study reveals that metformin may serve as a protective factor for BD, providing new theoretical basis for the application of metabolic intervention in the prevention and treatment of mental illness.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045112","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:44Z","timestamp":1761332504000},"page":"e45112","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mendelian randomization analysis reveals causal effects of metformin on bipolar disorder risk"],"prefix":"10.1097","volume":"104","author":[{"given":"Zhitao","family":"Li","sequence":"first","affiliation":[{"name":"Psychological Clinic, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Third Hospital of OuanZhou, Quanzhou, Fujian Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Psychological Clinic, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Third Hospital of OuanZhou, Quanzhou, Fujian Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"21r14045","DOI":"10.4088\/JCP.21r14045","article-title":"Prevalence of bipolar disorder in perinatal women: a systematic review and meta-analysis.","volume":"83","author":"Masters","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1017\/S0033291722002136","article-title":"Brain age and cognitive functioning in first-episode bipolar disorder.","volume":"53","author":"Chakrabarty","year":"2023","journal-title":"Psychol Med"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"609487","DOI":"10.3389\/fnbeh.2021.609487","article-title":"Concepts of neuroinflammation and their relationship with impaired mitochondrial functions in bipolar disorder.","volume":"15","author":"Cyrino","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tins.2017.10.006","article-title":"The emerging neurobiology of bipolar disorder.","volume":"41","author":"Harrison","year":"2018","journal-title":"Trends Neurosci"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/14782715231197577","article-title":"Bipolar disorder: diagnosis, treatment and future directions.","volume":"53","author":"Lane NMSmith","year":"2023","journal-title":"J R Coll Physicians Edinb"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/7854_2020_148","article-title":"Neuropsychology of bipolar disorder.","volume":"48","author":"Gallagher","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"e13816","DOI":"10.1111\/obr.13816","article-title":"The epigenetic mechanism of metabolic risk in bipolar disorder.","volume":"25","author":"Huang","year":"2024","journal-title":"Obes Rev"},{"key":"R8-20261118","doi-asserted-by":"crossref","first-page":"18m12422","DOI":"10.4088\/JCP.18m12422","article-title":"High prevalence of metabolic syndrome among adolescents and young adults with bipolar disorder.","volume":"80","author":"Li","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jad.2022.12.072","article-title":"Cardiovascular risk in bipolar disorder \u2013 a case for the hypothalamus\u2013pituitary\u2013adrenal axis?","volume":"324","author":"Knedeisen","year":"2023","journal-title":"J Affect Disord"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2147\/DDDT.S409373","article-title":"Metformin: a review of potential mechanism and therapeutic utility beyond diabetes.","volume":"17","author":"Dutta","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12974-019-1549-6","article-title":"Metformin mediates neuroprotection and attenuates hearing loss in experimental pneumococcal meningitis.","volume":"16","author":"Muri","year":"2019","journal-title":"J Neuroinflammation"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"102439","DOI":"10.1016\/j.arr.2024.102439","article-title":"Emerging role of metformin in Alzheimer\u2019s disease: a translational view.","volume":"100","author":"Rios","year":"2024","journal-title":"Ageing Res Rev"},{"key":"R13-20261118","doi-asserted-by":"crossref","first-page":"110262","DOI":"10.1016\/j.neuropharm.2024.110262","article-title":"Metformin activates the PI3K\/AKT\/BDNF axis to attenuate postoperative cognitive dysfunction.","volume":"265","author":"Wu","year":"2025","journal-title":"Neuropharmacology"},{"key":"R14-20261118","doi-asserted-by":"crossref","first-page":"149138","DOI":"10.1016\/j.brainres.2024.149138","article-title":"Metformin alleviates reactive gliosis and neurodegeneration, improving cognitive deficit in a rat model of temporal lobe epilepsy.","volume":"1844","author":"Bojja","year":"2024","journal-title":"Brain Res"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"21m14022","DOI":"10.4088\/JCP.21m14022","article-title":"Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD study): a randomized, quadruple-masked, placebo-controlled clinical trial.","volume":"83","author":"Calkin","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R16-20261118","doi-asserted-by":"crossref","first-page":"a040980","DOI":"10.1101\/cshperspect.a040980","article-title":"Using mendelian randomization to improve the design of randomized trials.","volume":"11","author":"Ference","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R17-20261118","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/aje\/kwt084","article-title":"Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators.","volume":"178","author":"Pierce","year":"2013","journal-title":"Am J Epidemiol"},{"key":"R18-20261118","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants.","volume":"40","author":"Pierce","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R19-20261118","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies.","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R20-20261118","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S2215-0366(21)00286-8","article-title":"Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study.","volume":"8","author":"Jones","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"R21-20261118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator.","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R22-20261118","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome.","volume":"34","author":"Greco","year":"2015","journal-title":"Stat Med"},{"key":"R23-20261118","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41588-018-0164-2","article-title":"Publisher correction: detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"R24-20261118","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2022.09.002","article-title":"The role of metformin as a treatment for neuropsychiatric illness.","volume":"64","author":"Dodd","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"R25-20261118","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2337\/dc20-1561","article-title":"Antidiabetes agents and incident depression: a nationwide population-based study.","volume":"43","author":"Kessing","year":"2020","journal-title":"Diabetes Care"},{"key":"R26-20261118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/a-1936-3580","article-title":"Metformin is protective against the development of mood disorders.","volume":"56","author":"Lake","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"R27-20261118","doi-asserted-by":"crossref","first-page":"636174","DOI":"10.3389\/fpsyt.2021.636174","article-title":"Insulin resistance and blood\u2013brain barrier dysfunction underlie neuroprogression in bipolar disorder.","volume":"12","author":"Calkin","year":"2021","journal-title":"Front Psychiatry"},{"key":"R28-20261118","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1017\/S0007114521003974","article-title":"Interactions of dietary insulin index and dietary insulin load with brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in relation to cardiometabolic markers in Iranian diabetic patients: a cross-sectional study.","volume":"128","author":"Abaj","year":"2022","journal-title":"Br J Nutr"},{"key":"R29-20261118","doi-asserted-by":"crossref","first-page":"17084","DOI":"10.1038\/s41598-022-20945-7","article-title":"Metformin alleviates neurocognitive impairment in aging via activation of AMPK\/BDNF\/PI3K pathway.","volume":"12","author":"Ameen","year":"2022","journal-title":"Sci Rep"},{"key":"R30-20261118","doi-asserted-by":"crossref","first-page":"949","DOI":"10.14336\/AD.2019.0120","article-title":"Metformin alters locomotor and cognitive function and brain metabolism in normoglycemic mice.","volume":"10","author":"Li","year":"2019","journal-title":"Aging Dis"},{"key":"R31-20261118","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00109-024-02465-1","article-title":"Metformin improves cognitive dysfunction through SIRT1\/NLRP3 pathway-mediated neuroinflammation in db\/db mice.","volume":"102","author":"Hu","year":"2024","journal-title":"J Mol Med (Berl)"},{"key":"R32-20261118","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK.","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"R33-20261118","doi-asserted-by":"crossref","first-page":"20348","DOI":"10.1074\/jbc.M115.662114","article-title":"Metformin inhibits the production of reactive oxygen species from NADH: ubiquinone oxidoreductase to limit induction of interleukin-1beta (IL-1beta) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages.","volume":"290","author":"Kelly","year":"2015","journal-title":"J Biol Chem"},{"key":"R34-20261118","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3390\/brainsci14121199","article-title":"Mitochondrial dysfunction as a biomarker of illness state in bipolar disorder: a critical review.","volume":"14","author":"Gimenez-Palomo","year":"2024","journal-title":"Brain Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:02:06Z","timestamp":1795021326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":34,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045112","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}